Selection of a Protective T Cell-based HIV-1/FIV Vaccine

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection. HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as effectors that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate protective part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.

Detailed Description
-----------------
As a participant in this study a blood drawn will performed.

Official Title
-----------------
Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Other: HIV positive subjects
* Other: Non-infected control subjects


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects between 18 and 65 years old who are HIV positive Exclusion Criteria: Persons with other immune diseases that would result in autoimmunity or aberrant immune responses (such as subjects who have undergone chemotherapy within the past year).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV positive subjects<br>This group will provide a blood sample. | Other: HIV positive subjects<br>* This group will provide a blood sample.<br>|
| Non-infected control subjects<br>This group consist of de-identified blood samples from a commercial source. | Other: Non-infected control subjects<br>* This group will be de-identified blood samples from a commercial source.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T cell proliferation in response to viral epitopes |  | 120 hours (5 days) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokine production in response to viral epitopes |  | 24 hours (1 day) | 
| Cytotoxin production in response to viral epitopes |  | 8 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, vaccine, T cell